Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
65 hedge funds and large institutions have $210M invested in Marinus Pharmaceuticals, Inc in 2017 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 6 closing their positions.
450% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 6
78% more capital invested
Capital invested by funds: $118M → $210M (+$92.3M)
73% more call options, than puts
Call options by funds: $2.25M | Put options by funds: $1.3M
71% more funds holding
Funds holding: 38 → 65 (+27)
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$7.34M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
+$6.82M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$6.74M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$6.54M |
| 5 |
6CM
683 Capital Management
New York
|
+$3.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$21.3M |
| 2 |
DM
Deerfield Management
New York
|
-$7.95M |
| 3 |
PA
Perceptive Advisors
New York
|
-$3.67M |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$2.74M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.25M |
MRNS Hedge Fund Activity: Q4 2017 in Review
65 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q4 2017, worth a combined $210M — up 78% from $118M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new MRNS positions and 6 closed out — a net gain of 27 holders — while 15 added to existing stakes and 13 trimmed.
The largest buyer was Jennison Associates, adding an estimated $7.34M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $21.3M sold.
- 65 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q4 2017, up from 38 in Q3 2017.
- Funds reported $210M of Marinus Pharmaceuticals, Inc stock for Q4 2017, up 78% quarter-over-quarter.
- 33 funds opened new Marinus Pharmaceuticals, Inc positions in Q4 2017 and 6 closed out, a net change of +27 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q4 2017 was Jennison Associates, an estimated $7.34M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q4 2017 was EcoR1 Capital, an estimated $21.3M sold.
Based on aggregated 13F filings for Q4 2017.